Scharstuhl et al., 2003 - Google Patents
Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β/bone morphogenetic protein inhibitors during …Scharstuhl et al., 2003
View PDF- Document ID
- 7669933317290178698
- Author
- Scharstuhl A
- Vitters E
- van der Kraan P
- van den Berg W
- Publication year
- Publication venue
- Arthritis & Rheumatism: Official Journal of the American College of Rheumatology
External Links
Snippet
Objective Osteoarthritis (OA) is a joint disease characterized by osteophyte development, fibrosis, and articular cartilage damage. Effects of exogenous transforming growth factor β (TGFβ) isoforms and bone morphogenetic proteins (BMPs) suggest a role for these growth …
- 102000004887 Transforming Growth Factor beta 0 title abstract description 146
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scharstuhl et al. | Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β/bone morphogenetic protein inhibitors during experimental osteoarthritis | |
| Nagao et al. | Vascular endothelial growth factor in cartilage development and osteoarthritis | |
| Lories et al. | Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis | |
| Liu et al. | Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation | |
| Van Bezooijen et al. | Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist | |
| Abdelmagid et al. | Osteoactivin acts as downstream mediator of BMP‐2 effects on osteoblast function | |
| Van Der Kraan | The changing role of TGFβ in healthy, ageing and osteoarthritic joints | |
| US20220296580A1 (en) | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium | |
| Blom et al. | Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt‐induced signaling protein 1 | |
| Maes et al. | Soluble VEGF isoforms are essential for establishingepiphyseal vascularization and regulating chondrocyte development and survival | |
| Wu et al. | Induction of an osteoarthritis‐like phenotype and degradation of phosphorylated Smad3 by Smurf2 in transgenic mice | |
| Yu et al. | TGF‐β, BMPS, and their signal transducing mediators, Smads, in rat fracture healing | |
| Horie et al. | Intra-articular injection of human mesenchymal stem cells (MSCs) promote rat meniscal regeneration by being activated to express Indian hedgehog that enhances expression of type II collagen | |
| Safadi et al. | Expression of connective tissue growth factor in bone: its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo | |
| Lounev et al. | Identification of progenitor cells that contribute to heterotopic skeletogenesis | |
| Wu et al. | Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice | |
| Liu et al. | Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis | |
| Tang et al. | Fibroblast growth factor receptor 3 inhibits osteoarthritis progression in the knee joints of adult mice | |
| Blaney Davidson et al. | Reduced transforming growth factor-beta signaling in cartilage of old mice: role in impaired repair capacity | |
| Luo et al. | Pancreatic cancer cell‐derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo | |
| Wang et al. | Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease | |
| Tsumaki et al. | The role of bone morphogenetic proteins in endochondral bone formation | |
| Wu et al. | Insights on biology and pathology of HIF-1α/-2α, TGFα/BMP, Wnt/β-catenin, and NF-κB pathways in osteoarthritis | |
| Frara et al. | Transgenic expression of osteoactivin/gpnmb enhances bone formation in vivo and osteoprogenitor differentiation ex vivo | |
| Baugé et al. | Regulation and role of TGFβ signaling pathway in aging and osteoarthritis joints |